tirzepatide surmount-1 weight loss percent 72 weeks (ZEPBOUND) Approved for Chronic Management in Adults with Obesity β¨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or SURMOUNT-1 in @nejmπ β°72-week trial
Pay in 4 interest-free payments of $7.33 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Nov 11 - Nov 16




















.png)






